Expanded Access to Vepugratinib for Patients with FGFR3 Altered Solid Tumors

Sponsor: Eli Lilly and Company

Expanded Access
Sponsor score: 60

ClinicalTrials ID:NCT07675057

Provider View

This program allows patients with certain solid tumors, including urothelial carcinoma, to access the drug Vepugratinib if they have specific genetic changes and have no other treatment options available.

Patient Parameters

Program Overview

This expanded access program provides the opportunity for patients with solid tumors that have a specific genetic change in the FGFR3 gene to receive the drug Vepugratinib. This is intended for patients who have tried all other approved treatments and are not eligible for any ongoing clinical trials of Vepugratinib.

Eligibility Criteria

Inclusion Criteria

  • Have metastatic urothelial carcinoma or another solid tumor with a specific FGFR3 genetic change.
  • Have tried all other approved treatments, including erdafitinib for urothelial carcinoma.
  • Are not eligible for any current clinical trials involving Vepugratinib.

Exclusion Criteria

  • Currently participating in a clinical study of Vepugratinib.
  • Have a severe allergy to any ingredient in Vepugratinib.
  • Have eye problems like corneal keratopathy or retinal disorders, unless they are minor and not causing symptoms.
  • Have significant heart disease.
  • Are pregnant, breastfeeding, or planning to become pregnant during the study or within 6 months after the last dose.

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.